Literature DB >> 17179591

Effectiveness of needle/syringe exchange program in Tbilisi.

D Otiashvili1, N Gambashidze, E Kapanadze, G Lomidze, D Usharidze.   

Abstract

IDUs are under the high risk of HIV and other blood born diseases. In Georgia injecting drug use is associated with two third of registered HIV/AIDS cases. Majority of them are also infected with B and C Hepatitis. One of the main components of HIV/AIDS prevention among drug users is considered to be harm reduction programs, among them syringe exchange program. We conducted observational cohort study and performed interviewing participants of syringe exchange program using structured questionnaire. The interviewing was conducted at intake, after 3 months and at the end of the program. During interviewing we used risk assessment questionnaire which we have little adapted (Risk Assessment Battery, Navaline, et al, 1994). The data were statistically analysed using SPPS-11, 5 program. The aim of the study was to assess the efficacy of outreach and needle exchange programs in terms of reduction of HIV risk behavior of injection drug users in Tbilisi. The results of the study show visible reduction in injection risk behavior for clients being in the program for at least three months. There was not seen any significant change in the level of sexual risk behavior, which might suggest the need for targeting this behavior during the further interventions. The results of the study suggest a visible potential benefit to drug users and communities that could be gained through the wide scale implementation of harm reduction programs in Georgia.

Entities:  

Mesh:

Year:  2006        PMID: 17179591

Source DB:  PubMed          Journal:  Georgian Med News        ISSN: 1512-0112


  1 in total

1.  Drug use and HIV risk outcomes in opioid-injecting men in the Republic of Georgia: behavioral treatment + naltrexone compared to usual care.

Authors:  David Otiashvili; Irma Kirtadze; Kevin E O'Grady; Hendrée E Jones
Journal:  Drug Alcohol Depend       Date:  2011-07-13       Impact factor: 4.492

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.